Evaxion Biotech A/S — Form 6-K Summary
Business context and reporting period
Evaxion Biotech A/S filed this Form 6-K on February 24, 2023, covering corporate and financing events during February 2023. The filing reports sales under the company’s at-the-market offering and resolutions adopted at its February 21, 2023 extraordinary general meeting.
Financial and capital markets highlights
- Between January 24 and February 17, 2023, the company sold 1,142,881 American Depositary Shares, or ADSs, under its ATM program.
- The ADSs were sold at an aggregate volume-weighted average price of $1.89 per ADS.
- Net proceeds after fees and expenses were approximately $2,185,098.
- The issuances increased nominal share capital by DKK 1,142,881, bringing total nominal share capital to DKK 26,421,727.
- The filing does not provide revenue, profit or loss, cash-flow, margin, debt, or liquidity figures for the reporting period.
Material changes and corporate actions
- At the February 21 extraordinary general meeting, 7,860,770 ordinary shares, representing 29.75% of outstanding ordinary shares as of the meeting date, were voted.
- Shareholders approved an amendment authorizing the board, until May 1, 2027, to issue up to 30,000,000 investor warrants representing up to DKK 30,000,000 of nominal share capital, without pre-emptive rights. The warrants may be issued to investors, lenders, consultants, and advisers at a minimum exercise price determined to be at least market price at issuance.
- Shareholders also approved an authorization, effective until May 1, 2027, for the board to increase share capital by up to DKK 44,170,262 through cash contributions without pre-emptive rights. Shares may be issued at market price or at a discount to the listed ADS price, as determined by the board.
- The company’s Articles of Association were amended to reflect the share issuances and approved authorizations.
Outlook, risks, and unusual items
The filing provides no operating guidance or financial forecast. The ATM sales provide additional funding but dilute existing shareholders. The approved warrant and share-issuance authorizations could result in substantial future dilution and may permit issuances below the listed ADS price, subject to the board’s terms and applicable requirements.
Key facts for investors to verify
- Actual use of the approximately $2.2 million in net ATM proceeds and the company’s cash runway.
- Future ADS or ordinary-share issuances under the DKK 44,170,262 capital authorization.
- Any warrants issued under the authorization for up to 30,000,000 warrants and their exercise prices, terms, and dilution impact.
- Updated outstanding share count following the ATM transactions and any subsequent issuances.
- Financial results, debt, liquidity, operating performance, and management guidance, which are not included in this 6-K.